KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Capital Expenditures (2017 - 2024)

Historic Capital Expenditures for Bionano Genomics (BNGO) over the last 7 years, with Q2 2024 value amounting to $77000.0.

  • Bionano Genomics' Capital Expenditures fell 8392.48% to $77000.0 in Q2 2024 from the same period last year, while for Mar 2025 it was $77000.0, marking a year-over-year decrease of 9432.57%. This contributed to the annual value of $103000.0 for FY2024, which is 9390.89% down from last year.
  • Bionano Genomics' Capital Expenditures amounted to $77000.0 in Q2 2024, which was down 8392.48% from $26000.0 recorded in Q1 2024.
  • Bionano Genomics' Capital Expenditures' 5-year high stood at $1.6 million during Q4 2022, with a 5-year trough of -$223000.0 in Q3 2022.
  • Over the past 4 years, Bionano Genomics' median Capital Expenditures value was $360000.0 (recorded in 2023), while the average stood at $440000.0.
  • As far as peak fluctuations go, Bionano Genomics' Capital Expenditures surged by 14798.21% in 2023, and later tumbled by 9277.78% in 2024.
  • Quarter analysis of 4 years shows Bionano Genomics' Capital Expenditures stood at $638000.0 in 2021, then soared by 143.1% to $1.6 million in 2022, then crashed by 51.97% to $745000.0 in 2023, then tumbled by 89.66% to $77000.0 in 2024.
  • Its last three reported values are $77000.0 in Q2 2024, $26000.0 for Q1 2024, and $745000.0 during Q4 2023.